Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Target Immune vs GEMOX in Unresectable ICC
NCT05247996Unknown
- Sponsor
- Lishui City Central Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Randomised, open-label trial of lenvatinib, donafenib, sintilimab and tislelizumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Lishui City Central Hospital. Primary endpoint: Progression-free Survival at 2 years. Status: unknown.
02
Drugs
lenvatinibdonafenibsintilimabtislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05247996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247996.